Meaney C, Kumagi T, Al-Harthy N, et al. Developing end points for clinical trials in PBC: alkaline phosphatase as a predictor of outcome. J Hepatol 2011; 54(Suppl S363-354):1296.Meaney C, Kumagi T, Al-Harthy N, et al. Developing end points for clinical trials in PBC: alkaline ...
term trials, all are showing us that the surrogate markers, alkaline phosphatase and bilirubin levels, seem to predict more optimal clinical outcomes. It lends credence to what we do in practice: trying to optimize and lower those laboratory values to have real clinical outcomes that benefit ...
medwireNews: Biochemical response to ursodeoxycholic acid (UDCA) at 6 months is a better predictor for primary biliary cirrhosis (PBC) prognosis than the current standard of 1 year, study results suggest. The authors say their findings indicate that early determination of prognosis should be used ...
These approaches are an important part of holistic care but are very difficult indeed to address in clinical trials. Conclusions 1. Since UDCA does not effectively treat fatigue, newer therapies are needed. Non-response of fatigue to UDCA just means that UDCA is not an effective treatment and ...
Through diary pages and news feeds we will be able to ensure that very few people miss the opportunity to take part in clinical trials, fundraising events, self-management workshops and much more besides. What’s New Version History 28 May 2021 ...
These phenotypic groups are all current treatment targets including UDCA unresponsive disease, fatigue and pruritus. The patients within the cohort are consented to be approached about participating in clinical trials. Across the UK we have a network of participating centres able to design and deliver...
The study was registered on the platform ClinicalTrials.gov under ID: NCT02557360. Serum samples were collected at 5 different time points (i.e. 0, 2, 4, 12 and 24 weeks). All the included patients fulfilled the European Association for the Study of the Liver (EASL) criteria for the ...
achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of...
The statements in this press release regarding the potential for seladelpar to treat NASH or PBC, the potential benefits to patients, CymaBay’s expectations and plans regarding its current and future clinical trials and CymaBay’s ability to fund current and planned clinical t...
Free Trials Top Rated Dividend Investing Value Investing Options Trading Growth Stocks Biotech Investing Tech Stocks Quantitative Investing Learn Investing Resources Investing Education Investing Strategies Retirement Investing Stock Market Sectors Stock Market Holidays & Hours After Hours Tr...